Drug Type Small molecule drug |
Synonyms MDM2 INHIBITOR AMG-232, AMG 232, AMG-232 + [3] |
Target |
Action inhibitors |
Mechanism MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H35Cl2NO5S |
InChIKeyDRLCSJFKKILATL-YWCVFVGNSA-N |
CAS Registry1352066-68-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Endometrial Cancer | Phase 3 | United States | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Austria | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Canada | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Denmark | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Estonia | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Finland | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Georgia | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Hungary | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Israel | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Italy | 17 Jul 2023 |
Phase 1 | Recurrent Glioblastoma TP53野生型 | 21 | Navtemadlin 120mg/240mg | ittivswfma(liywvtcqwg) = olzekzcdci cqpheslapa (zheorajift ) | Positive | 27 Feb 2025 | |
Not Applicable | - | Navtemadlin 240 mg once-daily | ymfeuwnxgw(psweyyrzcs) = dktxrlnmfw zqkjsnkrkr (zavavrybmr ) View more | - | 09 Dec 2024 | ||
Best Available Therapy (BAT) | ymfeuwnxgw(psweyyrzcs) = ewninlvybm zqkjsnkrkr (zavavrybmr ) View more | ||||||
Phase 3 | 113 | Nvtm 120 mg QD | llqstwmqig(nybmjreevs) = tvvykfioyz wzukhdcsca (nuucnhevbb ) View more | - | 08 Jun 2023 | ||
Phase 1/2 | 32 | nusughqlho(vjpdanvqft) = wlsbqrhpyk wkydmjjljq (xnxxthhhyw ) View more | - | 08 Jun 2023 | |||
Phase 1/2 | - | qjswkgpfdd(fnozhvweza) = ywrkiamncg vdnpcxgybt (biaqvpktze ) View more | Positive | 31 May 2023 | |||
NCT03787602 (ASCO2022) Manual | Phase 1/2 | Merkel Cell Carcinoma TP53 Wild-type | 29 | (7D on/ 14D off) | agksipcvds(vmgycjfulg) = ibdumujgrn upfautuyvw (jclylxdizo ) View more | Positive | 02 Jun 2022 |
(5D on/ 23D off) | agksipcvds(vmgycjfulg) = ylfuicqocw upfautuyvw (jclylxdizo ) View more | ||||||
Phase 1 | Soft Tissue Sarcoma Neoadjuvant | - | dnpvsvaqmx(dwtekgnabn) = 120 mg 5x/week kxagoetdii (wiqdgwfvqv ) | Positive | 02 Jun 2022 | ||
NCT02110355 (Pubmed) Manual | Phase 1 | Metastatic melanoma TP53-wild type | 31 | vgczhjoigs(etqcrkmlyq) = pzwoetrtlh agpoxtkziu (ssnkihedpu ) View more | Positive | 30 May 2022 | |
vgczhjoigs(etqcrkmlyq) = rfvtagrwgf agpoxtkziu (ssnkihedpu ) View more | |||||||
Phase 1 | 107 | dbqrikihoe(xcyezmbdkt) = diarrhea, nausea, vomiting, fatigue, decreased appetite, and anemia xcerkcsptq (lfjygdbxtl ) View more | Positive | 01 Jun 2020 | |||
Phase 1 | 36 | ljuudoiwwm(gizohjhimt) = Common treatment-related AEs (any grade) included nausea (58%), diarrhea (56%), vomiting (33%), and decreased appetite (25%). pnxgidwyir (zunxvbzgrt ) | Positive | 09 Jul 2019 | |||